Clinical Trials
12 trialsNCT00070382 2020-08-03
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Jonsson Comprehensive Cancer Center
Phase 3 Completed
NCT00656448 2018-05-30
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00416624 2017-02-10
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
Mayo Clinic
Phase 2 Completed
NCT00058331 2016-07-18
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00003600 2016-07-13
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00482716 2014-01-10
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003341 2013-07-03
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00053001 2013-06-26
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00255749 2012-10-04
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01099202 2012-08-27
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
M.D. Anderson Cancer Center
Phase NA Completed
NCT00261677 2011-05-23
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Ortho Biotech Products, L.P.
Phase 3 Completed
NCT00270049 2011-05-18
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed